These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20542845)

  • 21. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
    Lieberman-Blum SS; Fung HB; Bandres JC
    Clin Ther; 2008 Jul; 30(7):1228-50. PubMed ID: 18691983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load.
    Treviño A; Soriano V; Poveda E; Parra P; Cabezas T; Caballero E; Roc L; Rodríguez C; Eiros JM; Lopez M; De Mendoza C;
    J Antimicrob Chemother; 2014 Aug; 69(8):2191-4. PubMed ID: 24788659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical utility of maraviroc.
    Parra J; Portilla J; Pulido F; Sánchez-de la Rosa R; Alonso-Villaverde C; Berenguer J; Blanco JL; Domingo P; Dronda F; Galera C; Gutiérrez F; Kindelán JM; Knobel H; Leal M; López-Aldeguer J; Mariño A; Miralles C; Moltó J; Ortega E; Oteo JA
    Clin Drug Investig; 2011; 31(8):527-542. PubMed ID: 21595497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States.
    Hornberger J; Kilby JM; Wintfeld N; Green J
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):240-7. PubMed ID: 16545010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
    Flynn JK; Ellenberg P; Duncan R; Ellett A; Zhou J; Sterjovski J; Cashin K; Borm K; Gray LR; Lewis M; Jubb B; Westby M; Lee B; Lewin SR; Churchill M; Roche M; Gorry PR
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1220-1235. PubMed ID: 28797170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Maraviroc efficacy in clinical studies on the development of the molecule].
    Moreno S; Hernández B; Gutiérrez C; Delsol E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():17-22. PubMed ID: 19133217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc.
    Dentone C; Sterrantino G; Signori A; Cenderello G; Guerra M; De Leo P; Bartolacci V; Mantia E; Orofino G; Giacomini M; Bruzzone B; Francisci D; Di Biagio A;
    Int J STD AIDS; 2017 Oct; 28(11):1067-1073. PubMed ID: 28142395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients.
    Tiraboschi JM; Niubo J; Curto J; Podzamczer D
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):606-9. PubMed ID: 20706127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maraviroc.
    Carter NJ; Keating GM
    Drugs; 2007; 67(15):2277-88; discussion 2289-90. PubMed ID: 17927288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.
    Bonjoch A; Pou C; Pérez-Álvarez N; Bellido R; Casadellà M; Puig J; Noguera-Julian M; Clotet B; Negredo E; Paredes R
    J Antimicrob Chemother; 2013 Jun; 68(6):1382-7. PubMed ID: 23354282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
    Broder MS; Chang EY; Bentley TG; Juday T; Uy J
    J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.
    Yost R; Pasquale TR; Sahloff EG
    Am J Health Syst Pharm; 2009 Apr; 66(8):715-26. PubMed ID: 19336831
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Gracias S; El Yaalaoui I; Visseaux B; Charpentier C; Descamps D; Martin C; Lermechain F; Plantier J-C; Alessandri-Gradt E
    Microbiol Spectr; 2024 Jul; 12(7):e0389523. PubMed ID: 38809042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The utility of genotypic tropism testing in clinical practice.
    Wyatt H; Herman OM; Macartney M; Conibear T; Garcia-Diaz A; Booth C; McCormick A; Smith C; Johnson MA; Irish D; Webster DP
    Int J STD AIDS; 2015 Jul; 26(8):593-4. PubMed ID: 25147237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of maraviroc on HIV disease progression-related biomarkers.
    Romero-Sánchez MC; Machmach K; Gonzalez-Serna A; Genebat M; Pulido I; García-García M; Alvarez-Ríos AI; Ferrando-Martinez S; Ruiz-Mateos E; Leal M
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5858-64. PubMed ID: 22948867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
    Bredeek UF; Harbour MJ
    Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice.
    Potard V; Reynes J; Ferry T; Aubin C; Finkielsztejn L; Yazdanpanah Y; Costagliola D;
    PLoS One; 2015; 10(12):e0144746. PubMed ID: 26714012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two new drugs for HIV infection.
    Med Lett Drugs Ther; 2008 Jan; 50(1277):2-4. PubMed ID: 18197163
    [No Abstract]   [Full Text] [Related]  

  • 39. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
    van Lelyveld SF; Drylewicz J; Krikke M; Veel EM; Otto SA; Richter C; Soetekouw R; Prins JM; Brinkman K; Mulder JW; Kroon F; Middel A; Symons J; Wensing AM; Nijhuis M; Borghans JA; Tesselaar K; Hoepelman AI;
    PLoS One; 2015; 10(7):e0132430. PubMed ID: 26208341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.